Orgenesis Stock Valuation

ORGS -  USA Stock  

USD 4.78  0.13  2.65%

How much is Orgenesis worth today? Calculating the true value of any business is not as easy as it may seem. While the market cap of a public entity, such as Orgenesis, is its stock price multiplied by the total number of shares outstanding, calculating Orgenesis' enterprise value requires a different approach. It uses Orgenesis' balance sheet items such as long-term debt, the book value of the preferred stock, minority interest, and other important financials.
Orgenesis holds a recent Real Value of $5.66 per share. The prevailing price of the company is $4.78. At this time, the company appears to be undervalued. Our model determines the value of Orgenesis from analyzing the company fundamentals such as Return On Equity of (122.25) %, current valuation of 102.92 M, and Shares Owned by Insiders of 5.47 % as well as examining its technical indicators and Probability Of Bankruptcy. In general, we support buying undervalued entities and selling overvalued entities since, at some point, asset prices and their ongoing real values will merge together.

Search Valuation 

 
Refresh
Orgenesis Valuation Module provides a unique way to ballpark how much the company is worth today. It is done using both, our quantitative analysis of the company fundamentals as well as its intrinsic market price estimation to project the real value. We also take into consideration other essential factors such as Orgenesis's management style, its c-level domain expertise and tenure, its overall leadership history as well as current capital structure, and future earnings potential.
Undervalued
Today
4.78
28th of July 2021
Share
Please note that Orgenesis' price fluctuation is relatively risky at this time. Calculation of the real value of Orgenesis is based on 3 months time horizon. Increasing Orgenesis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Orgenesis is useful when determining the fair value of the Orgenesis stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Orgenesis. Since Orgenesis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Orgenesis Stock. However, Orgenesis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
5.66
Real Value
11.19
Upside
Estimating the potential upside or downside of Orgenesis helps investors to forecast how Orgenesis stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Orgenesis more accurately as focusing exclusively on Orgenesis' fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.544.955.37
Details
Hype
Prediction
LowEstimated ValueHigh
0.244.7810.31
Details
Naive
Forecast
LowNext ValueHigh
0.105.1210.64
Details
1 Analysts
Consensus
LowTarget PriceHigh
9.009.009.00
Details

Orgenesis Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Orgenesis's current stock value. Our valuation model uses many indicators to compare Orgenesis value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Orgenesis competition to find correlations between indicators driving Orgenesis's intrinsic value. More Info.
Orgenesis is rated below average in price to book category among related companies. It is rated below average in price to sales category among related companies fabricating about  3.61  of Price to Sales per Price to Book.

About Orgenesis Valuation

The equity valuation mechanism determines the current worth of Orgenesis on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Orgenesis. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Orgenesis based exclusively on its fundamental and basic technical indicators. By analyzing Orgenesis's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Orgenesis's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Orgenesis. We calculate exposure to Orgenesis's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Orgenesis's related companies.
Orgenesis Inc., a biotech company, focusing on cell and gene therapies . The company was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 111 people.

Orgenesis Valuation Growth Rates

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Orgenesis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Quick Ratio2.82
Revenue Growth399.90%
Enterprise Value To Ebitda-1.17
Enterprise Value To Revenue6.79
Please check Your Equity Center. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Transaction History module to view history of all your transactions and understand their impact on performance.

Complementary Tools for Orgenesis Stock analysis

When running Orgenesis price analysis, check to measure Orgenesis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Orgenesis is operating at the current time. Most of Orgenesis' value examination focuses on studying past and present price action to predict the probability of Orgenesis' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Orgenesis' price. Additionally, you may evaluate how the addition of Orgenesis to your portfolios can decrease your overall portfolio volatility.
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
The market value of Orgenesis is measured differently than its book value, which is the value of Orgenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Orgenesis' value that differs from its market value or its book value, called intrinsic value, which is Orgenesis' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Orgenesis' market value can be influenced by many factors that don't directly affect Orgenesis underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Orgenesis' value and its price as these two are different measures arrived at by different means. Investors typically determine Orgenesis value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Orgenesis' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.